ERBB2 and non-small cell lung carcinoma: However, at the 2020 ASCO Meeting preliminary results of the phase 2 DESTINY Lung-01 trial (ClinicalTrials.gov Identifier: NCT03505710) demonstrated encouraging activity of trastuzumab deruxtecan treatment, a novel ADC, in patients (n=42) with relapsed/refractory HER2-mutant NSCLC enrolled in the cohort 2 of the study.